PR 016
Alternative Names: PR-016Latest Information Update: 22 Dec 2023
At a glance
- Originator Paragon Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 22 Dec 2023 Discontinued for Unspecified in USA (Parenteral) (Paragon Therapeutics pipeline, December 2023)
- 14 Jul 2023 Early research in Unspecified in USA (Parenteral) (Paragon Therapeutics pipeline, July 2023)